Following an unanimous endorsement from its advisory board, the FDA has amended the emergency use authorisations for a third dose of the Moderna and Johnson & Johnson vaccines in vulnerable populations.
The Moderna booster can offered to those 65 or over or younger adults at high risk of severe COVID-19 or with ‘frequent institutional or occupational exposure to SARS-CoV-2’ at least six months after the second dose.
The indication for a booster to the single-shot Johnson & Johnson is wider, covering any adult that received the first shot and with a much shorter space of two months between the first single-shot and the booster.
